34-Week Data Analysis from Second Clinical Trial of Bausch & Lomb's Retisert Implant for Posterior Uveitis is Presented At The Retina Society Annual Meeting.

ROCHESTER, N.Y. -- Bausch & Lomb (NYSE: BOL)

--Implanted Eyes Showed Statistically Significant Decrease in Uveitis Recurrence Rate Post-implantation; And as Compared to Fellow Eye

--Visual Acuity Improved by At Least Three Lines in 21 Percent of Eyes

--Adverse Events were Managed by Conventional Means

Analysis of 34-week results of an international, randomized, dose-masked, multi-center clinical trial designed to assess the safety and efficacy of the Retisert(TM) implant for the treatment of non-infectious posterior uveitis were presented by principal investigator Dr. Robert Devenyi, Ophthalmologist-in-Chief and Director of Retinal Services at the University Health Network and professor of ophthalmology at the University of Toronto, Canada, at the Annual Meeting of the Retina Society in Baltimore, Maryland on Saturday, October 2, 2004. This trial was designed to confirm the results of the first pivotal trial of the implant, which were reported in 2003.

The data presented by Dr. Devenyi relate to a trial conducted at 19 centers in Canada, the United States, Australia, India, the Philippines and Hong Kong. 239 patients with non-infectious posterior uveitis were randomized to receive either a 0.59 mg or a 2.1 mg Retisert implant in the affected eye or, in bilateral cases, in the more severely afflicted eye. The fellow eye was implant free.

Devenyi reported that for the aggregate results of the two doses at 34 weeks, the uveitis recurrence rate (the targeted outcome of this trial) was statistically lower (p less than 0.0001) in those eyes with the Retisert implant (10.0 percent) compared to the recurrence rate in the fellow eyes (55.7 percent). There was also statistically significant improvement in visual acuity (p less than 0.05) in the implanted eyes, but no statistically significant change in mean visual acuity in the fellow eyes. Importantly, 20.9 percent of the implant eyes had an improvement in vision of three or more lines.

Overall, at 34 weeks, there was a statistically significant decrease in the use of systemic corticosteroid and/or immunosuppressant therapy, use of periocular injections and use of topical steroid eye drops to control inflammation in implanted eyes.

At 34 weeks the most common adverse events included cataract progression and increased intraocular pressure - which were anticipated given the nature of the disease and the type of drug used, and were managed by conventional means.

"These results solidly confirm the results of the first pivotal trial and show that this drug delivery technology, combined with the well-known steroid fluocinolone acetonide, reduces the recurrence of posterior uveitis," said Gary M. Phillips MD, vice president-global pharmaceuticals for Bausch & Lomb. "The unmasked results of the two trials will be submitted to the U.S. Food and Drug Administration for approval of the Retisert implant for the treatment of posterior uveitis and we continue to target commercialization in 2005."

This news release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of Bausch & Lomb. Such statements involve a number of risks and uncertainties including, without limitation, those concerning global and local economic, political and sociological conditions; currency exchange rates; government pricing changes and initiatives with respect to healthcare products; changes in laws and regulations relating to the Company's products and the import and export of such products; product development and rationalization; enrollment and completion of clinical trials; the ability of the Company to obtain regulatory approvals; the outcome of litigation; the success of product introductions; the financial well-being of key customers, development partners and suppliers; the successful execution of marketing strategies; the continued successful implementation of the Company's efforts in managing and reducing costs and expenses; the Company's success in the process of management testing and auditor attestation of internal controls, as required under the Sarbanes-Oxley Act of 2002; the Company's success in introducing and implementing its enterprise-wide information technology initiatives, including the corresponding impact on controls and reporting; continued positive relations with third party financing sources and the risk factors listed from time to time in the Company's SEC filings, including but not limited to the current report on Form 8-K, dated June 14, 2002 and the Form 10-Q for the quarter ended, June 26, 2004.

Bausch & Lomb is the eye health company, dedicated to perfecting vision and enhancing life for consumers around the world. Its core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products. The Bausch & Lomb name is one of the best known and most respected healthcare brands in the world. Celebrating its 150th anniversary, the Company is headquartered in Rochester, New York. Bausch & Lomb's 2003 revenues were $2 billion; it employs approximately 11,500 people worldwide and its products are available in more than 100 countries. More information about the Company can be found on the Bausch & Lomb Web site at www.bausch.com. Copyright Bausch & Lomb.